HCC TILs are phenotypically exhausted with high expression of inhibitory immune checkpoints, such as TIM-3 and LAG3,112 suggesting that combination therapy with ICIs may be required to maximise their utility in HCC. The gene discussed is HAVCR2; the disease is hepatocellular carcinoma.